Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting.

Benzer Materyaller

• Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting
  Yazar:: Abernethy, Amy P., ve diğerleri
  Baskı/Yayın Bilgisi: (2017)
• Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma
  Yazar:: Cai, Weijing, ve diğerleri
  Baskı/Yayın Bilgisi: (2015)
• Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations
  Yazar:: Lou, Na-Na, ve diğerleri
  Baskı/Yayın Bilgisi: (2016)
• Intratumor Heterogeneity of ALK-Rearrangements and Homogeneity of EGFR-Mutations in Mixed Lung Adenocarcinoma
  Yazar:: Marino, Federica Zito, ve diğerleri
  Baskı/Yayın Bilgisi: (2015)
• Concomitant EGFR mutations/ALK rearrangements: beyond a simple dual target
  Yazar:: Galetta, Domenico, ve diğerleri
  Baskı/Yayın Bilgisi: (2016)